

Abstracts

A71

medical and prescription claims collected over a 4-year study period (January 1, 2001–December 31, 2004) from more than 300,000 employees. Data from employees with and without (controls) functional dyspepsia were compared using 2-part regression techniques. Outcome measures included direct and indirect costs paid by the employer, absenteeism, direct costs by the place of service where care was performed, and objectively measured productivity output. **RESULTS:** Employees with functional dyspepsia ($N = 1669$) had greater average annual direct medical and prescription drug costs and indirect costs (due to sick leave, short- and long-term disability absences) than controls ($N = 274,206$). Compared with controls, the functional dyspepsia employees incurred health benefit costs that were \$5,138 greater and had greater costs for each place of service (all $P < 0.0001$). The employees with functional dyspepsia had an additional 0.83 absence days per year and produced 12% fewer units per hour than controls (both $P < 0.05$). **CONCLUSIONS:** Employees with functional dyspepsia have greater costs at all places of service and lower productivity than employees without functional dyspepsia.

PGI13

THE DISEASE BURDEN OF IRRITABLE BOWEL SYNDROME IN KOREAKim Y¹, Jang B¹, Park S¹, Park J¹, Nam M¹, Jung HK², Choi MG³

¹National Evidence-based health care Collaborating Agency, Seoul, South Korea, ²Ewha Womans University School of Medicine, Seoul, South Korea, ³College of Medicine, The Catholic University of Korea, Seoul, South Korea

OBJECTIVES: The aim of this study was to estimate the annual societal disease burden of irritable bowel syndrome (IBS) in Korea for the year of 2008. **METHODS:** The claim data with IBS were extracted from the Health Insurance Review & Assessment Service database in 2008 of Korea. After definition of patient with specialists, the prevalence and medical costs were calculated. The number of outpatient visits and length of hospital stay also were calculated to estimate transportation cost and productivity loss. **RESULTS:** The annual national patients with IBS were estimated to 1.30 million with 753,688 (57.79%) for female. The results showed that the crude prevalence of IBS was 2.68% (95%CI: 2.66%-2.71%, 2.25% for male and 3.12% for female) in 2008. The total cost due to IBS was 14.9 billion won (1\$ = 1047.30 won, 2008) including 348 million won for direct medical cost (2.33%), 88 million won for nonmedical cost (transportation costs), and 14.5 billion won for lost work due to illness. **CONCLUSIONS:** The disease burden of IBS appears to be high because of the high morbidity although not a significant cause of death. The result is likely to underestimate due to using claim data and strict definition of patient. However, this data might be useful and necessary to support evidence based decision making for IBS.

PGI14

DIRECT AND INDIRECT COSTS OF HEPATITIS C VIRUS (HCV): COMPARISON OF NON-HCV, UNTREATED HCV, AND PEG-RBV TREATED HCV COHORTSBonafede M¹, Pan K¹, Wilson K¹, Solomon M², Spiegel B³, Beam C⁴, Chakravarti P⁵

¹Thomson Reuters, Cambridge, MA, USA, ²Stanford School of Medicine, Stanford, CA, USA, ³David Geffen School of Medicine at UCLA, Los Angeles, CA, USA, ⁴Human Genome Sciences, Inc., Rockville, MD, USA, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

OBJECTIVES: To compare direct and indirect costs between HCV patients on pegylated interferon with ribavirin (PEG-RBV), untreated HCV, and non-HCV controls. **METHODS:** We identified three cohorts using the MarketScan Commercial Claims and Encounters Database[®] from 2002–2007: HCV patients on PEG-RBV, untreated HCV, and non-HCV controls. We used propensity scores to match treated to untreated (1:1), and HCV to non-HCV patients (1:3). We compared direct costs and utilization across the cohorts. We performed subset analysis using the MarketScan Health and Productivity Management Database[®] to evaluate absenteeism and short-term disability costs. **RESULTS:** We identified 10,001 PEG-RBV patients. Compared to untreated patients, treated patients had higher total medical costs (\$28,547 vs. \$21,752; $p < 0.001$) outpatient pharmacy costs (\$17,419 vs. \$2,900; $p < 0.001$) and outpatient physician visit costs (\$894 vs. \$787; $p < 0.001$), but lower inpatient costs (\$3,942 vs. \$9,543; $p < 0.001$) and ER costs (\$366 vs. \$505; $p < 0.001$). Treated patients had similar absenteeism rates (93% vs. 88%; $p = 0.27$), higher short-term disability rates (33% vs. 30%; $p < 0.001$) and higher indirect costs (\$11,528 vs. \$9,316; $p < 0.05$). Non-HCV controls had significantly lower costs in all categories compared to patients with HCV. Total costs among matched non-HCV costs were \$15,932, outpatient pharmacy costs were \$1,796, outpatient physician visit costs were \$429, inpatient costs were \$2,181, and ER costs were \$184; indirect costs were \$7,654. After adjusting for demographic and clinical characteristics, including HIV and cirrhosis, differences remained significant but diminished. **CONCLUSIONS:** HCV patients engender a higher economic burden compared to non-HCV controls. Treated patients cost more than untreated patients; the cost differential is primarily driven by higher outpatient pharmacy costs. Indirect cost differences are driven by greater absenteeism duration and greater short term disability use and duration. These data provide insight into the economic burden of HCV and its treatment, and may be employed in future health economic analyses evaluating existing and emerging therapies.

PGI15

MEDICAL SERVICE UTILIZATION AND COSTS BY DISEASE SEVERITY, SUSTAINED VIRAL RESPONSE, AND GENOTYPE IN EUROPEAN PATIENTS WITH CHRONIC HEPATITIS C VIRUSDavis KL¹, Mitra D¹, Leteneux C², Bapat B¹, Naujoks C²

¹RTI Health Solutions, Research Triangle Park, NC, USA, ²Novartis Pharma AG, Basel, Switzerland

OBJECTIVES: To document variations in resource utilization and costs by disease severity, sustained viral response (SVR), and genotype in a European population with chronic hepatitis C virus (C-HCV). **METHODS:** Patient charts from the UK, France, Germany, Spain, and Italy were retrospectively reviewed. Inclusion criteria were: C-HCV diagnosis within past 5 years; age ≥ 18 years; no diagnoses of hepatitis B or HIV/AIDS; ≥ 1 year follow-up post-diagnosis; no clinical trial participation. All-cause utilization and costs (2009 €) for hospitalizations, emergency room (ER) and office visits, and specialty referrals were aggregated within patients over 1 year post-diagnosis. C-HCV severity was assessed via Metavir score. Among patients receiving C-HCV-directed pharmacotherapy, SVR was defined by viral RNA < 10 IU/mL at ≥ 6 months post-treatment. Utilization and cost differences across clinical factors were assessed with multivariate modeling. **RESULTS:** In total, 1016 patients were identified. Overall, 23% of severe patients were hospitalized versus 2.5% of mild. Hospitalization was 5 times more likely in severe C-HCV compared to mild (odds ratio [OR] = 5.39; $P = 0.008$), while the hospitalization rate, measured by Poisson incidence rate ratio (IRR), was 4 times higher (IRR = 3.98; $P = 0.010$). Hospital costs were €1380 higher in severe versus mild disease ($P = 0.001$). Hospitalization risk in SVR attainers was less than half that of non-attainers (OR = 0.22; $P < 0.0001$). ER, office, and specialist visit rates were significantly lower among SVR attainers. Genotype had little effect on utilization, but genotype 1 was associated with slightly lower (€90 per patient; $P < 0.0001$) hospital costs versus genotypes ≥ 2 . **CONCLUSIONS:** Disease severity and SVR are important predictors of C-HCV costs. Awareness of these factors by public health systems, which bear the high cost burden of C-HCV, may help promote strategies for earlier disease detection and increased treatment initiation before progression occurs, as well as formulary access for more convenient therapies that increase treatment persistence and thereby SVR rates.

PGI16

PATTERNS OF LUBIPROSTONE UTILIZATION AND COSTS IN MEMBERS OF A LARGE HEALTH BENEFITS COMPANYSussman D¹, Tamariz L¹, Drooge M², Harkins T³, Ma Q³, Uribe C³, Hanna JW⁴

¹University of Miami Leonard Miller School of Medicine, Miami, FL, USA, ²Takeda Pharmaceuticals America, Deerfield, IL, USA, ³University of Miami Humana Health Services Research Center, Miami, FL, USA, ⁴Navigenics Inc, Foster City, CA, USA

OBJECTIVES: Assess patterns of utilization and costs of twice daily 24 mcg dosing of lubiprostone in a large managed care population. **METHODS:** Patients included Humana members 18 years and older with medical claims for chronic constipation (CC) and/or irritable bowel syndrome (IBS) between April 1, 2006 and April 30, 2008. The index date was the first diagnosis of CC or IBS. Patients had at least 180-days of continuous enrollment pre-index and at least 30-days post-index. Users and non-users were compared. Users were compared pre- and post-lubiprostone initiation. **RESULTS:** A total of 92,804 patients with a diagnosis of CC or IBS were identified during the study period; 1873 filled at least one 30-day prescription for lubiprostone. Seventy-five percent of users were female. Lubiprostone users were younger than non-users (61.6 vs. 66.2 yrs old) and more likely to be co-prescribed opiates (35.5 vs. 29.4%), anti-histamines (14.8 vs. 9.5%) and tricyclic antidepressants (8.1 vs. 4.7%), all statistically significant. Common co-morbidities in lubiprostone users were back problems (23.6%) and abdominal pain (21.9%). A total of 1605 users had both 6-months pre- and post-lubiprostone initiation data. A total of 42.2% of these patients filled more than one 30-day lubiprostone prescription; 6.42% filled 6 or more. Usage of other prescription laxatives decreased by 4.6% ($p < 0.05$) subsequent to lubiprostone initiation. Monthly health care costs per utilizing member increased by \$67.10 ($p < 0.0001$). Pharmacy costs rose by \$71.73 ($p < 0.0001$) and ER costs decreased by \$8.12 ($p < 0.05$). Pre-post changes in outpatient and inpatient costs were not significant. Monthly inpatient and ER visits for these 1605 members decreased by 0.31 and 0.08 per utilizing member respectively ($p < 0.05$) in the 6-months after starting lubiprostone. Changes in outpatient visits were not significant. **CONCLUSIONS:** Lubiprostone users were younger females who were co-prescribed opiates and had back problems. Higher health care costs were offset by a decrease in ER costs.

PGI17

COST-EFFECTIVENESS ANALYSIS OF TREATMENT WITH PEGINTERFERON-ALFA-2A VERSUS PEGINTERFERON-ALFA-2B FOR PATIENTS WITH GENOTYPES 2/3 CHRONIC HEPATITIS C UNDER THE PUBLIC PAYER PERSPECTIVE IN BRAZILBarros FMR¹, Cheinquer H², Borges LG³, Santos E²

¹Hospital Português de Beneficência em Pernambuco and Hospital das Clínicas - UFPE, Recife, Brazil, ²Hospital das Clínicas da Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ³Roche Brazil, São Paulo, Brazil

Hepatitis C affects approximately 180 million people worldwide and is one of the main causes of chronic liver disease. HCV infection progresses to chronicity in approximately 80% of infected individuals, from whom up to 20% can develop cirrhosis over 20 years, thus presenting high risk of complications related to hepatic insufficiency and/or hepatocellular carcinoma. **OBJECTIVES:** To compare treatment costs and outcomes of peginterferon-alfa-2a versus peginterferon-alfa-2b, both associated

with ribavirin, in the therapeutic scheme of 24 weeks for hepatitis C genotype 2/3 in Brazilian Public Health System (SUS). **METHODS:** To project disease progression, a Markov model was built based on clinical stages of chronic disease. A Delphi panel was conducted to evaluate direct medical resources related to each stage, followed by micro-costing of the results. Perspective was from a public payer. Source used for costing was government reimbursement procedures list (SAI/SIH-SUS). Drug acquisition costs for a 70 kg patient were obtained from 'Banco de Preços em Saúde', government official source. Costs were reported in 2009 Brazilian Reais (US\$1=\$Brz1.7). Efficacy of pegylated-interferons was obtained from a meta-analysis of 7 RCTs comparing the drugs, detailed elsewhere. For genotype 2/3, median rate of sustained virological response was 79.2% for peginterferon-alfa-2a and 73.8% for peginterferon-alfa-2b. Discount rate for costs and outcomes was 5%, according to Brazilian guidelines for HTA. **RESULTS:** Assuming a lifetime perspective, expected costs and outcomes for peginterferon-alfa-2a were \$Brz15,898, 15.21LYs and 14.57QALYs; for peginterferon-alfa-2b, \$Brz18,439, 15.11LYs and 14.32QALYs. Cost-effectiveness analysis estimated an ICER of -\$Brz25,289/LY and -\$Brz10,426/QALYs for peginterferon-alfa-2a, being the dominant therapy. For each 1000 patients treated with peginterferon-alfa-2a instead of peginterferon-alfa-2b, savings granted can be up to \$Brz2,5 million which would allow treatment of 160 more patients. **CONCLUSIONS:** These findings suggest that treatment with peginterferon-alfa-2a is more effective and less costly when compared to peginterferon-alfa-2b under SUS perspective in Brazil.

PGI18

COST-EFFECTIVENESS ANALYSIS OF TREATMENT WITH PEGINTERFERON-ALFA-2A VERSUS PEGINTERFERON-ALFA-2B FOR PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C UNDER THE PUBLIC PAYER PERSPECTIVE IN BRAZIL

Barros FMR¹, Cheinquer H², Borges LG³, Santos E³

¹Hospital Português de Beneficência em Pernambuco and Hospital das Clínicas - UFPE, Recife, Brazil, ²Hospital das Clínicas da Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ³Roche Brazil, São Paulo, Brazil

Chronic hepatitis C affects approximately 180 million people worldwide being one of the main causes of chronic liver disease. About 20% of patients with chronic hepatitis C can develop cirrhosis over 20 years, thus presenting risk of developing hepatic complications. Treatment is currently based on pegylated-interferon-alfa-2a or alfa-2b plus ribavirin. Sustained virologic response (SVR) is associated with a better prognosis compared to untreated patients and treatment failures. **OBJECTIVES:** To compare treatment costs and outcomes of peginterferon-alfa-2a versus peginterferon-alfa-2b, both plus ribavirin, in the therapeutic scheme of 48 weeks for hepatitis C genotype 1 in Brazilian Public Health System (SUS). **METHODS:** To project disease progression, a Markov model was built based on clinical stages of chronic disease. A Delphi panel was conducted to evaluate direct medical resources related to each stage, followed by micro-costing of results. Perspective was from a public payer. Costing was based on government reimbursement procedures list (SAI/SIH-SUS). Drug acquisition costs (70 kg patient) were obtained from 'Banco de Preços em Saúde', government source. Costs were in 2009 Brazilian Reais (US\$1=\$Brz1.7). Efficacy of pegylated-interferons was obtained from a meta-analysis of 7 RCTs comparing the drugs, detailed elsewhere. For genotype 1, SVR median rate was 42.1% for peginterferon-alfa-2a and 33.3% for peginterferon-alfa-2b. Discount rate (costs and outcomes) was 5%, according to Brazilian guidelines for HTA. **RESULTS:** Assuming a lifetime perspective, expected costs and outcomes for peginterferon-alfa-2a were \$Brz36,713, 14.51LYs and 12.89QALYs; for peginterferon-alfa-2b \$Brz41,191, 14.35LYs and 12.49QALYs gained. Cost-effectiveness analysis estimated an ICER of -\$Brz27,266/LY and -\$Brz11,277/QALY for peginterferon-alfa-2a, being the dominant therapy. For each 1000 patients treated with peginterferon-alfa-2a instead of peginterferon-alfa-2b, savings granted can be up to \$Brz4.4 million which would allow treatment of 120 more patients. **CONCLUSIONS:** Findings suggest that treatment with peginterferon-alfa-2a is more effective and less costly when compared to peginterferon-alfa-2b under SUS perspective in Brazil.

PGI19

COST-EFFECTIVENESS ANALYSIS OF TREATMENT WITH PEGINTERFERON-ALFA-2A VERSUS PEGINTERFERON-ALFA-2B FOR PATIENTS WITH GENOTYPES 2/3 CHRONIC HEPATITIS C UNDER THE PRIVATE PAYER PERSPECTIVE IN BRAZIL

Barros FMR¹, Cheinquer H², Borges LG³, Santos E³

¹Hospital Português de Beneficência em Pernambuco and Hospital das Clínicas - UFPE, Recife, Brazil, ²Hospital das Clínicas da Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ³Roche Brazil, São Paulo, Brazil

Hepatitis C affects approximately 180 million people worldwide and is currently one of the main causes of chronic liver disease. HCV infection progresses to chronicity in up to 80% of infected individuals, from whom approximately 20% progress to cirrhosis over 20 years. These individuals are at risk of developing hepatic failure and/or hepatocellular carcinoma. **OBJECTIVES:** To compare treatment costs and outcomes of peginterferon-alfa-2a versus peginterferon-alfa-2b, both associated with ribavirin, in the therapeutic scheme of 24 weeks for hepatitis C in Brazilian private market for the treatment of HCV infection genotypes 2/3. **METHODS:** To project disease progression, a Markov model was built based on clinical stages of chronic disease. A Delphi panel was conducted to evaluate direct medical resources related to each stage, followed by micro-costing of the results. The perspective was from a private payer. Source used for costing was medical society physicians fee list (CBHPM-2008). Drug acquisition costs for a 70kg patient were obtained from official public sources

(Kairos Magazine-Nov2009). Costs were reported in 2009 Brazilian Reais (US\$1=\$Brz1.7). Efficacy of pegylated-interferons was obtained from a meta-analysis of 7 RCTs comparing the drugs, detailed elsewhere. For genotype 2/3, median rate of sustained virological response was 79.2% for peginterferon-alfa-2a and 73.8% for peginterferon-alfa-2b. Discount rate for costs and outcomes was 5%, according to Brazilian guidelines for HTA. **RESULTS:** Assuming a lifetime perspective, expected costs and outcomes for peginterferon-alfa-2a were \$Brz48,363, 15.21LYs and 14.57QALYs; for peginterferon-alfa-2b, \$Brz52,154, 15.11LYs and 14.32QALYs. Cost-effectiveness analysis estimated an ICER of -\$Brz37,614/LY and -\$Brz15,556/QALYs for peginterferon-alfa-2a, being the dominant therapy. For each 1000 patients treated with peginterferon-alfa-2a instead of peginterferon-alfa-2b, savings granted can be up to \$Brz3.8 million which would allow treatment of 78 more patients. **CONCLUSIONS:** These findings suggest that treatment with peginterferon-alfa-2a is more effective and less costly when compared to peginterferon-alfa-2b under private payer perspective in Brazil.

PGI21

ECONOMIC ANALYSIS OF ALVIMOPAN FOR PREVENTION AND MANAGEMENT OF POST-OPERATIVE ILEUS

Yang Y¹, Touchette DR¹, Tiryaki F¹, Galanter W²

¹University of Illinois at Chicago, Chicago, IL, USA, ²The University of Illinois at Chicago, Chicago, IL, USA

OBJECTIVES: Whether the use of alvimopan is cost-effective, compared to the standard post-operative care, for post-operative ileus (POI) among patients undergoing small- or large-bowel resection via laparotomy. **METHODS:** We constructed a formal decision model from the health care system perspective. The clinical outcomes (time to discharge order written [DCO], post-operative nasogastric tube insertion, POI-related readmission within 7 days, nausea and vomiting) were obtained from meta-analyses of published studies. Cost inputs included costs associated with the drugs, nursing labor, readmission, and hospitalization. Cost-consequence was assessed by determining the net cost of alvimopan use and subsequent reduction in length of stay (LOS). Sensitivity analyses were conducted. **RESULTS:** The alvimopan drug cost was \$570 based on an average of 9.5 doses. Given the 18.4-hour mean reduction in DCO, the use of alvimopan reduced hospitalization costs by \$2021. In the base-case, alvimopan resulted in a \$1187 per-person cost savings. In sensitivity analyses, the result was robust to changes in key parameters including the cost and number of doses of alvimopan, DCO, readmission rates, and hospitalization cost. In scenario analyses, alvimopan use yielded a cost saving of \$897 when no difference in readmission rates was assumed. However, when no difference in DCO was assumed, the total cost of care with alvimopan was \$278 greater. Similarly, it was \$569 greater when both readmission rates and DCO were assumed to be equal between strategies. In Monte Carlo simulation, the mean difference in overall cost of care was \$1252 (95% certainty interval: -\$398 to \$6306), favoring the use of alvimopan. **CONCLUSIONS:** The overall hospitalization cost reduction associated with the use of alvimopan offsets the drug cost. Alvimopan appears to be cost-saving for POI among patients undergoing bowel resection via laparotomy. This finding is not applicable to the less-invasive laparoscopic surgical approach which has been associated with decreased post-operative morbidity and LOS.

PGI22

EVALUATION OF COST-EFFECTIVENESS OF CHRONIC HEPATITIS B TREATMENTS: ENTECAVIR AND TELBIVUDINE

Suh JK, Hay J

University of Southern California, Los Angeles, CA, USA

OBJECTIVES: The aim of this study was to evaluate the cost-effectiveness of entecavir and telbivudine in HBeAg-positive/-negative chronic hepatitis B (CHB) patients based on the ability of each drug to suppress viral replication. **METHODS:** A cost-effectiveness analysis was performed to evaluate the impact of treatment on disease morbidity and costs over the lifetime and the short term (10 years) for a patient based on a societal perspective. A decision tree was developed to assess the drug abilities to suppress HBV DNA replication. To obtain probability estimates with HBV DNA levels and resistance rates of entecavir and telbivudine, recent entecavir-lamivudine BEHoLD studies and telbivudine-lamivudine GLOBE studies were indirectly compared. The risks of progression to compensated cirrhosis (CC), decompensated cirrhosis (DC), or HCC were derived from the REVEAL-HBV study, which was to evaluate the relationship between hepatitis B viremia and progression to cirrhosis and HCC. For the life expectancy of DC and HCC, the declining exponential approximation of life (DEALE) method was applied based on the published annual mortality rates of DC and HCC. Both direct and indirect medical costs were included and univariate sensitivity analyses were performed on parameters in the model to evaluate the impact of parameter uncertainty. **RESULTS:** On a per-person basis, the ICERs of entecavir compared to telbivudine for lifetime therapy were \$13,649 and \$52,776 in HBeAg-positive and HBeAg-negative CHB, respectively. In the 10-year model, the ICERs were \$US 39,089 and \$US 365,100 in HBeAg-positive and HBeAg-negative CHB, respectively. One-way sensitivity analyses showed that the model was robust to most parameters. However, parameters such as drug costs, discount rate and average time to events from study entry were sensitive. **CONCLUSIONS:** For lifetime therapy and for HBeAg-positive patients, entecavir was cost effective compared to telbivudine. However, in the short-term treatment model for HBeAg-negative CHB, entecavir was not cost-effective.